By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

The New England Journal of Medicine 

10 Shattuck Street

Boston  Massachusetts  02115-6094  U.S.A.
Phone: 617-734-9800 Fax: 617-739-9864


SEARCH JOBS


Industry
Services

Segment
Publisher





Company News
PALOMA-2 Phase 3 Study Published In The New England Journal of Medicine Demonstrates Clinical Benefit Of Pfizer (PFE)’s IBRANCE(palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer 11/17/2016 11:43:09 AM
Janssen Pharmaceutical Companies Release: Phase 3 Study Results Supporting U.S. FDA And European Commission (EC) Approvals Of STELARA In The Treatment Of Moderately To Severely Active Crohn's Disease Published In The New England Journal of Medicine 11/17/2016 7:17:31 AM
Alnylam (ALNY) And The Medicines Company (MDCO) Announce Publication Of Phase 1 Clinical Data With Inclisiran (ALN- PCSsc) In The New England Journal of Medicine 11/14/2016 12:24:27 PM
The New England Journal of Medicine Publishes Study On Zika Genomic Sequence Identification By IDbyDNA 9/29/2016 8:22:50 AM
GlaxoSmithKline (GSK) And Innoviva Release: Positive Results From The COPD Salford Lung Study Published In The The New England Journal of Medicine And Presented At European Respiratory Congress 9/6/2016 1:34:34 PM
Agendia BV Release: The New England Journal of Medicine Publishes MINDACT Trial Results Proving The Clinical Utility Of Mammaprint In Assisting Physicians To Identify Early-Stage Breast Cancer Patients Who Can Safely Forgo Chemotherapy 8/25/2016 8:49:21 AM
Pivotal Study Results Published In The New England Journal of Medicine Confirm Safety And Efficacy Of InSightec's Exablate Neuro System For The Treatment Of Essential Tremor 8/25/2016 6:56:24 AM
Intercept Pharma (ICPT) Release: The New England Journal of Medicine Publishes Results Of Phase III POISE Trial Of Ocaliva (Obeticholic Acid) For The Treatment Of PBC 8/18/2016 8:13:09 AM
Rhythm Announces The New England Journal of Medicine Publication Of Setmelanotide Phase 2 Data For Treatment Of POMC Deficiency Obesity 7/21/2016 6:31:10 AM
Puma Biotech (PBYI) Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal of Medicine 7/7/2016 10:51:30 AM
12345678910...
//-->